Daiwa Securities Group
KALV

Daiwa Securities Group’s KalVista Pharmaceuticals KALV Stock Holding History

Daiwa Securities Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-154
Closed -$2K – 1317
2025
Q4 		$2K Hold
154
– – ﹤0.01% 1312
2025
Q3 		$2K Hold
154
– – ﹤0.01% 1273
2025
Q2 		$2K Hold
154
– – ﹤0.01% 1215
2025
Q1 		$2K Hold
154
– – ﹤0.01% 1184
2024
Q4 		$1K Hold
154
– – ﹤0.01% 1255
2024
Q3 		$2K Hold
154
– – ﹤0.01% 1220
2024
Q2 		$2K Hold
154
– – ﹤0.01% 1252
2024
Q1 		$2K Buy
+154
New +$2.05K ﹤0.01% 1270
2022
Q4 		– Sell
-46
Closed -$1K – 1344
2022
Q3 		$1K Hold
46
– – ﹤0.01% 1293
2022
Q2 		$0 Hold
46
– – ﹤0.01% 1392
2022
Q1 		$1K Hold
46
– – ﹤0.01% 1312
2021
Q4 		$1K Hold
46
– – ﹤0.01% 1340
2021
Q3 		$1K Hold
46
– – ﹤0.01% 1271
2021
Q2 		$1K Hold
46
– – ﹤0.01% 1197
2021
Q1 		$1K Buy
46
+12
+35% +$315 ﹤0.01% 1204
2020
Q4 		$1K Buy
+34
New +$583 ﹤0.01% 1184

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Daiwa Securities Group's KALV Position: Q1 2026 in Review

Daiwa Securities Group sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 154 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in KALV in Q4 2020 and held it in 16 quarters. The position peaked at $2K in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Daiwa Securities Group reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 154 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2K.
  • Daiwa Securities Group first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 16 quarters.
  • Daiwa Securities Group's KalVista Pharmaceuticals position peaked at $2K in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.